ReviewMedicina (Kaunas, Lithuania)2019
Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants.
Review in Medicina (Kaunas, Lithuania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Association between atrial fibrillation and gastrointestinal bleeding: pathophysiology, risk stratification, and management - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms and Emerging Therapeutic Targets.Biomolecules · 2026Review
- Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Trends and cost structure of drug-based secondary prevention of ischemic strokes.Neurological research and practice · 2025Article
- Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus.Biomedicines · 2024Review
- Unveiling the Role of Endothelial Dysfunction: A Possible Key to Enhancing Catheter Ablation Success in Atrial Fibrillation.International journal of molecular sciences · 2024Review
- All-Cause Death and Major Adverse Events in Atrial Fibrillation with Frailty: Observations from the Korea National Health Insurance Service Data.Reviews in cardiovascular medicine · 2024Article
- Patients with Atrial Fibrillation are Unlikely to Benefit from Aspirin Monotherapy.International journal of general medicine · 2024Article
- Local Tranexamic Acid for Preventing Hemorrhage in Anticoagulated Patients Undergoing Dental and Minor Oral Procedures: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2022Review
- Analysis of Adverse Events in the Treatment of Patients with Non-Valvular Atrial Fibrillation with Oral Anticoagulants: Data from the "ANTEY" Observational Study.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Warfarin-Induced Calcification: Potential Prevention and Treatment Strategies.Reviews in cardiovascular medicine · 2022Review
- "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.Journal of clinical medicine · 2022Review
- Warfarin Adherence Among Patients with Atrial Fibrillation in Rural Area of Dongyang, China: A Questionnaire-Based Study.Patient preference and adherence · 2022Article
- Economy- and Social-Based Strategies for Anticoagulation of Patients with Atrial Fibrillation.Arquivos brasileiros de cardiologia · 2022Article
- Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort.Biomedicines · 2021Review
- Treatment Pattern of Antithrombotic Therapy over Time after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation in Real-World Practice in Korea.Healthcare (Basel, Switzerland) · 2021Article
- Could DOAC Be a Better Choice Than Warfarin in Low Compliance Patients with Fontan Procedure?Medicina (Kaunas, Lithuania) · 2021Article
- Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease.Medicina (Kaunas, Lithuania) · 2021Review
- Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. One important issue is represented by the 5-fold increased ischemic stroke risk in AF patients. Hence, the role of anticoagulation is central. Until a few years ago, vitamin K antagonists (VKAs) and low molecular weight heparin represented the only option to prevent thromboembolisms, though with risks. Novel oral anticoagulants (NOACs) have radically changed the management of AF patients, improving both life expectancy and life quality. This review aims to summarize the most recent literature on the use of VKAs and NOACs in AF, in light of the new findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.